These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23790554)

  • 21. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
    Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
    Trials; 2011 Jan; 12():4. PubMed ID: 21208417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does early-onset chronic or recurrent major depression impact outcomes with antidepressant medications? A CO-MED trial report.
    Sung SC; Wisniewski SR; Balasubramani GK; Zisook S; Kurian B; Warden D; Trivedi MH; Rush AJ;
    Psychol Med; 2013 May; 43(5):945-60. PubMed ID: 23228340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
    Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
    CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trajectories of individual symptoms in remitters versus non-remitters with depression.
    Sakurai H; Uchida H; Abe T; Nakajima S; Suzuki T; Pollock BG; Sato Y; Mimura M
    J Affect Disord; 2013 Nov; 151(2):506-513. PubMed ID: 23886402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. What predicts attrition in second step medication treatments for depression?: a STAR*D Report.
    Warden D; Rush AJ; Wisniewski SR; Lesser IM; Kornstein SG; Balasubramani GK; Thase ME; Preskorn SH; Nierenberg AA; Young EA; Shores-Wilson K; Trivedi MH
    Int J Neuropsychopharmacol; 2009 May; 12(4):459-73. PubMed ID: 18611293
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Depression symptom dimensions as predictors of antidepressant treatment outcome: replicable evidence for interest-activity symptoms.
    Uher R; Perlis RH; Henigsberg N; Zobel A; Rietschel M; Mors O; Hauser J; Dernovsek MZ; Souery D; Bajs M; Maier W; Aitchison KJ; Farmer A; McGuffin P
    Psychol Med; 2012 May; 42(5):967-80. PubMed ID: 21929846
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting 6-week treatment response to escitalopram pharmacotherapy in late-life major depressive disorder.
    Saghafi R; Brown C; Butters MA; Cyranowski J; Dew MA; Frank E; Gildengers A; Karp JF; Lenze EJ; Lotrich F; Martire L; Mazumdar S; Miller MD; Mulsant BH; Weber E; Whyte E; Morse J; Stack J; Houck PR; Bensasi S; Reynolds CF
    Int J Geriatr Psychiatry; 2007 Nov; 22(11):1141-6. PubMed ID: 17486678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Depression Subtypes Among Men in STAR*D: A Latent Transition Analysis.
    Ulbricht CM; Dumenci L; Rothschild AJ; Lapane KL
    Am J Mens Health; 2018 Jan; 12(1):5-13. PubMed ID: 26438468
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ECT Has Greater Efficacy Than Fluoxetine in Alleviating the Burden of Illness for Patients with Major Depressive Disorder: A Taiwanese Pooled Analysis.
    Lin CH; Huang CJ; Chen CC
    Int J Neuropsychopharmacol; 2018 Jan; 21(1):63-72. PubMed ID: 29228200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.
    IsHak WW; Mirocha J; James D; Tobia G; Vilhauer J; Fakhry H; Pi S; Hanson E; Nashawati R; Peselow ED; Cohen RM
    Acta Psychiatr Scand; 2015 Jan; 131(1):51-60. PubMed ID: 24954156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical and functional outcomes of patients who experience partial response to citalopram: secondary analysis of STAR*D.
    Dennehy EB; Marangell LB; Martinez J; Balasubramani GK; Wisniewski SR
    J Psychiatr Pract; 2014 May; 20(3):178-87. PubMed ID: 24847991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Machine Learning Prediction of Quality of Life Improvement During Antidepressant Treatment of Patients With Major Depressive Disorder: A STAR*D and CAN-BIND-1 Report.
    Phaterpekar T; Nunez JJ; Morton E; Liu YS; Cao B; Frey BN; Milev RV; Müller DJ; Rotzinger S; Soares CN; Taylor VH; Uher R; Kennedy SH; Lam RW
    J Clin Psychiatry; 2023 Nov; 85(1):. PubMed ID: 37967350
    [No Abstract]   [Full Text] [Related]  

  • 33. Brief, unidimensional melancholia rating scales are highly sensitive to the effect of citalopram and may have biological validity: implications for the research domain criteria (RDoC).
    Ostergaard SD; Bech P; Trivedi MH; Wisniewski SR; Rush AJ; Fava M
    J Affect Disord; 2014 Jul; 163():18-24. PubMed ID: 24836083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.
    Trivedi MH; Rush AJ; Wisniewski SR; Nierenberg AA; Warden D; Ritz L; Norquist G; Howland RH; Lebowitz B; McGrath PJ; Shores-Wilson K; Biggs MM; Balasubramani GK; Fava M;
    Am J Psychiatry; 2006 Jan; 163(1):28-40. PubMed ID: 16390886
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Developing brief scales for use in clinical practice: the reliability and validity of single-item self-report measures of depression symptom severity, psychosocial impairment due to depression, and quality of life.
    Zimmerman M; Ruggero CJ; Chelminski I; Young D; Posternak MA; Friedman M; Boerescu D; Attiullah N
    J Clin Psychiatry; 2006 Oct; 67(10):1536-41. PubMed ID: 17107244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-term disability in major depressive disorder: a 6-year follow-up study.
    Iancu SC; Wong YM; Rhebergen D; van Balkom AJLM; Batelaan NM
    Psychol Med; 2020 Jul; 50(10):1644-1652. PubMed ID: 31284881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Income and attrition in the treatment of depression: a STAR*D report.
    Warden D; Rush AJ; Wisniewski SR; Lesser IM; Thase ME; Balasubramani GK; Shores-Wilson K; Nierenberg AA; Trivedi MH
    Depress Anxiety; 2009; 26(7):622-33. PubMed ID: 19582825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, randomized, double-blind, flexible-dose study.
    Ou JJ; Xun GL; Wu RR; Li LH; Fang MS; Zhang HG; Xie SP; Shi JG; Du B; Yuan XQ; Zhao JP
    Psychopharmacology (Berl); 2011 Feb; 213(2-3):639-46. PubMed ID: 20340011
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cognitive reactivity to sad mood provocation and the prediction of depressive relapse.
    Segal ZV; Kennedy S; Gemar M; Hood K; Pedersen R; Buis T
    Arch Gen Psychiatry; 2006 Jul; 63(7):749-55. PubMed ID: 16818864
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.